1. The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model 
Matthew O'Brien, Thuy Quach, Deborah Gilbert, Michael N. Dudley, Stephen H. Zinner 
Clinical Microbiology and Infection 
Volume 5, Issue 1, Pages (January 1999)
DOI: /j tb00092.x
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Time course of central compartment antibiotic concentrations: (a) ciprofloxacin simulated at 750 mg every 12 h; (b) trovafloxacin simulated at 300 mg (▪) and 200 mg (▴) every 24 h.
Clinical Microbiology and Infection 1999 5, 12-15DOI: ( /j tb00092.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Mean of duplicate bacterial counts for six strains of Streptococcus pneumoniae exposed to simulated trovafloxacin dosing at 300 mg every 24 h in an in vitro dynamic model.
Clinical Microbiology and Infection 1999 5, 12-15DOI: ( /j tb00092.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Mean of duplicate bacterial counts for the same six strains of Streptococcus pneumoniae as in Figure 2 exposed to simulated ciprofloxacin dosing at 750 mg every 12 h in an in vitro dynamic model.
Clinical Microbiology and Infection 1999 5, 12-15DOI: ( /j tb00092.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

5. Figure 4
Mean of duplicate bacterial counts for three strains of Streptococcus pneumoniae exposed to simulated trovafloxacin dosing at 200 mg every 24 h (a) and to ciprofloxacin dosing at 750 mg every 12 h (b).
Clinical Microbiology and Infection 1999 5, 12-15DOI: ( /j tb00092.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions